Navigation Links
Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Date:5/15/2008

ANN ARBOR, Mich. and TOULOUSE, France, May 15 /PRNewswire/ -- Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced that it has completed a Phase I clinical trial for CER-002, one of the company's lead product candidates. CER-002 is a peroxisome proliferator-activated receptor (PPAR) delta-specific agonist in development for the treatment of cardiovascular diseases.

CER-002 is the most advanced small molecule HDL candidate in Cerenis' portfolio. It was developed from new chemical entities that are specific agonists for human PPAR delta, a multifaceted therapeutic target with broad potential for the treatment of cardiovascular and metabolic diseases. In preclinical models, CER-002 has demonstrated strong efficacy in elevating HDL and in halting the progression of atherosclerosis. It was selected for clinical development from a series of small molecule compounds available to Cerenis through a licensing agreement with Nippon Chemiphar Co., Ltd.

"CER-002 is a novel compound which has shown significant antiatherosclerotic properties in animal models even at low doses. The completion of our first clinical trial represents an important milestone for Cerenis, further validating our promising technology platform and our expanding library of investigational compounds to treat atherosclerosis. As we move forward with the clinical development program for CER-002, we will also continue planning clinical stage development programs for the other promising product candidates in our portfolio," said Jean-Louis Dasseux, Ph.D., M.B.A., president and CEO of Cerenis.

The Phase I study for CER-002 was a randomized, double-blind, placebo-controlled, cross-over, single-rising dose study conducted with healthy male volunteers. Objectives of the study included assessments of the safety, tolerability, and pharmacokinetics of CER-002 when
'/>"/>

SOURCE Cerenis Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/12/2014)... United Arab Emirates (PRWEB) July 12, 2014 ... another Los Angeles basketball legend is heading to the ... scorer and six-time champion will be in the UAE ... & Fitness Weekend in support of diabetes awareness. The ... an award-winning entertainment marketing and event management company based ...
(Date:7/12/2014)... Columbus, OH (PRWEB) July 12, 2014 Wright ... representing clients in Just For Men Lawsuits (case ... to inform consumers of reports that allege the popular hair ... serious chemical burns to their face, neck and other areas. ... of Just For Men chemical burns , the advertisements being ...
(Date:7/12/2014)... 12, 2014 Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... 12, 2014 Recently, MagicQuinceaneraDresses.com, the popular ... new collection of 2014 Quinceanera dresses . The ... want to look fashionable without paying a large amount ... up to 57% off. , The company’s online shop ... get amazing special occasion outfits. In addition to exquisite ...
(Date:7/11/2014)... 2014 According to new report ... is expected to register a CAGR of 2.28% ... 71 market data tables and 76 figures spread ... Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will ... , The report provides market analysis of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... Magnetic resonance imaging (MRI) findings in patients about to undergo ... that the cancer will return and spread post-treatment, according to ... journal Radiology. , This is the first study to show ... cancer outside the capsule of the prostate is an important ...
... have fewer symptoms of anxiety or depression, while children ... have difficulties forming relationships and being accepted by friends. ... and depression lead to the social problems, or vice ... likely to contribute to anxiety and depression than the ...
... toxic gas responsible for the unpleasant odor of rotten ... aspects of cardiovascular function in mice, producing a suspended-animation-like ... journal Anesthesiology, Massachusetts General Hospital (MGH) reseachers report that ... not depend on a reduction in body temperature and ...
... Responder For Saving Life of ... Femoral Artery, WALLINGFORD, Conn., March 24 Executives ... X. Hursey,Award to Rockland Paramedic Services (RPS) Medic 21 ... QuikClot(R) 1st Response(TM) brand,hemostatic agent to save the life ...
... WASHINGTON, March 24 The following are,remarks by Kent ... of World Tuberculosis Day 2008:, Although a cure ... a,century, TB remains one of three leading causes of ... million people each year,while HIV/AIDS claims more than two ...
... guidance, BOSTON, March 24 AMICAS, Inc. ... medical image and information management,solutions, announced today that ... to AMICAS, board of directors while accepting his ... In addition, the company,has promoted Kevin C. Burns ...
Cached Medicine News:Health News:MRI findings help forecast prostate cancer prognosis 2Health News:Youth's social problems contribute to anxiety and depression 2Health News:Sewer-gas-induced suspended animation is rapid and reversible 2Health News:NY-Area Paramedic Wins 2007 Francis X. Hursey Award for Heroic Use of QuikClot(R) Blood Clotting Product 2Health News:NY-Area Paramedic Wins 2007 Francis X. Hursey Award for Heroic Use of QuikClot(R) Blood Clotting Product 3Health News:Statement from Kent Hill, USAID Assistant Administrator for Global Health, on the Observance of World Tuberculosis Day 2008 2Health News:Statement from Kent Hill, USAID Assistant Administrator for Global Health, on the Observance of World Tuberculosis Day 2008 3Health News:AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer 2Health News:AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer 3Health News:AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer 4
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation....
... Air Fluidized Therapy: ,Full-length air ... and provides greater comfort and accelerated ... system can be defluidized to facilitate ... Trendelenburg and Reverse Trendelenburg. CPR procedures ...
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
Medicine Products: